Is There an ARB That Controls BP Better Than Olmesartan?
Yes, azilsartan medoxomil (particularly at 80 mg) demonstrates superior blood pressure lowering compared to olmesartan and other ARBs, with the strongest evidence showing better 24-hour ambulatory and clinic BP reductions while maintaining similar safety profiles.
Evidence Hierarchy
The most recent and highest-quality evidence comes from a 2021 network meta-analysis 1 that directly compared multiple ARBs across 34 studies (n=14,859). This analysis found that azilsartan medoxomil 80 mg had a 99% probability of being the most efficacious ARB in the class for reducing both systolic and diastolic blood pressure.
Head-to-Head Comparative Data
The pivotal 2011 randomized controlled trial 2 (n=1,291) provides the strongest direct comparison evidence:
Azilsartan medoxomil 80 mg achieved superior 24-hour ambulatory systolic BP reduction (-14.3 mm Hg placebo-adjusted) compared to:
- Olmesartan 40 mg (-11.7 mm Hg; P=0.009)
- Valsartan 320 mg (-10.0 mm Hg; P<0.001)
Clinic BP reductions were similarly superior for both doses of azilsartan medoxomil versus comparator ARBs
Safety profiles were comparable across all active treatments
Efficacy in Diverse Populations
A 2018 post-hoc analysis 3 demonstrated that azilsartan medoxomil's superiority extends across racial groups:
- In both Black and White patients, azilsartan medoxomil 80 mg lowered clinic SBP by 12.5 mm Hg more than olmesartan (p<0.01)
- When combined with chlorthalidone, azilsartan medoxomil achieved even greater reductions than olmesartan/HCTZ combinations
Ranking Among All ARBs
A 2024 network meta-analysis 4 (193 studies) confirmed the relative efficacy rankings:
For office BP reduction:
- Olmesartan ranked highest (91.4% for SBP, 87.2% for DBP)
- Azilsartan medoxomil ranked second
For 24-hour ambulatory BP:
- Candesartan ranked highest for systolic (95.4%)
- Telmisartan ranked highest for diastolic (83.4%)
For safety profile:
- Olmesartan ranked highest (70.8%)
- Olmesartan and telmisartan had fewer adverse events than losartan
Clinical Algorithm for ARB Selection
First-line choice for maximum BP reduction:
- Azilsartan medoxomil 80 mg (superior 24-hour BP control)
Alternative high-efficacy options:
- Olmesartan 40 mg (excellent efficacy-safety balance, more established track record)
- Telmisartan 80 mg (good 24-hour coverage, favorable metabolic effects)
Consider patient-specific factors:
- Cost/availability: Olmesartan may be more accessible than azilsartan medoxomil
- Combination therapy needs: Both drugs have well-studied fixed-dose combinations
- Race: ARBs generally less effective in Black patients (low-renin population) 5; consider adding thiazide diuretic or calcium channel blocker
Important Caveats
Guideline perspective: Neither the 2024 ESC 6 nor 2017 ACC/AHA 7 guidelines distinguish between individual ARBs for efficacy—they treat the class as equivalent for cardiovascular outcomes
BP reduction vs. outcomes: While azilsartan medoxomil shows superior BP lowering, long-term cardiovascular outcome trials comparing it to olmesartan are lacking
Clinical significance: The 2-3 mm Hg difference in BP reduction between azilsartan medoxomil and olmesartan, while statistically significant, may have modest clinical impact for individual patients
Dose considerations: Olmesartan's FDA-approved maximum dose is 40 mg [@3,4@], while azilsartan medoxomil can be dosed up to 80 mg, potentially explaining some efficacy differences
Bottom Line
For patients requiring maximum BP reduction within the ARB class, switch from olmesartan to azilsartan medoxomil 80 mg. The evidence consistently demonstrates 2-3 mm Hg greater reductions in both ambulatory and clinic BP measurements [@6,8@]. However, olmesartan remains an excellent choice with strong efficacy, proven safety, and extensive real-world experience [@9,10,11@]. The decision should weigh the incremental BP benefit against cost, availability, and individual patient response.